• Vector Science & Therapeutics formed a strategic partnership with Caresyntax to build real-world evidence infrastructure for its VectorMist platform.
• Caresyntax will run a multi-phase program across partner surgical facilities, ending in a prospective comparative registry benchmarking outcomes versus standard care.
• Primary endpoints include postoperative opioid use, hospital length of stay, patient-reported pain scores.
• Parties will evaluate extending the same evidence architecture to Vector’s broader portfolio, including peptide therapeutics, subject to a separate agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607170810PR_NEWS_USPR_____LA06843) on July 17, 2026, and is solely responsible for the information contained therein.